Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson’s Disease Patients with Cognitive Deficits: A Meta-Analysis

Objectives. To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson’s disease (PD). Methods. Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disor...

Full description

Saved in:
Bibliographic Details
Published in:Parkinson's disease 2020, Vol.2020 (2020), p.1-8
Main Authors: Nair, N Sreekumaran, Selvarajan, Sandhiya, Ramakrishnan, Kirubakaran, Behera, Sapan Kumar, Das, Saibal, Ghosh, Abhinaba, Kandasamy, Preeti
Format: Article
Language:English
Subjects:
Attention
Bibliographic data bases
Clinical trials
Cognition
Cognition & reasoning
Cognitive ability
Comparative analysis
Disease
Dopamine
Drug dosages
Executive function
Memory
Mental disorders
Mental illness
Meta-analysis
Movement disorders
Neurodegenerative diseases
Parkinson's disease
Social discrimination learning
Social interactions
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson’s disease (PD). Methods. Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disorders-5) following administration of atomoxetine for at least 8 weeks in adults with idiopathic PD were included. Effect sizes (Cohen’s d), the standardized mean difference in the scores of each cognitive domain, were compared using a random-effects model (MetaXL version 5.3). Results. Three studies were included in the final analysis. For a change in complex attention in PD with mild cognitive impairment (MCI), the estimated effect size was small and nonsignificant (0.16 (95% CI: −0.09, 0.42), n = 42). For changes in executive function, perceptual-motor function, language, social cognition, and learning and memory, the estimated effect sizes were small and medium, but nonsignificant. A deteriorative trend in executive function was observed after atomoxetine treatment in PD with MCI. For a change in global cognitive function in PD without MCI, the estimated effect size was large and significant. Conclusion. In idiopathic PD with MCI, atomoxetine does not improve complex attention. Also, a deteriorative trend in the executive function was noted.
ISSN:2090-8083
2042-0080
DOI:10.1155/2020/4853590